Evidence map›Paper›PMID 32648210›Full record

ArticlePathology oncology research : POR2020

Prognostic Role of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Immunohistochemical Expression in Patients with Resected Gastric Carcinomas.

Cristina Díaz Del Arco, Lourdes Estrada Muñoz, Rodrigo Barderas Manchado, Alberto Peláez García, Luis Ortega Medina, Elena Molina Roldán, Guillermo Solís Fernández, Soledad García Gómez de Las Heras, Mª Jesús Fernández Aceñero

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Cristina Díaz Del ArcoComplutense University of Madrid, Madrid, Spain. crisdelarco@gmail.com.ORCID http://orcid.org/0000-0002-6100-4967
Lourdes Estrada MuñozRey Juan Carlos University, Madrid, Spain.
Rodrigo Barderas ManchadoCarlos III Health Institute (ISCIII), Madrid, Spain.
Alberto Peláez GarcíaHospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Luis Ortega MedinaComplutense University of Madrid, Madrid, Spain.
Elena Molina RoldánHospital Clínico San Carlos, Madrid, Spain.
Guillermo Solís FernándezCarlos III Health Institute (ISCIII), Madrid, Spain.
Soledad García Gómez de Las HerasRey Juan Carlos University, Madrid, Spain.
Mª Jesús Fernández AceñeroComplutense University of Madrid, Madrid, Spain.
Universidad Complutense de Madrid · ESInstituto de Salud Carlos III · ESUniversidad Rey Juan Carlos · ESHospital Clínico San Carlos · ESHospital La Paz Institute for Health Research · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aryl hydrocarbon receptor (AHR) interacting protein (AIP) is a chaperone which binds to inactive AHR in the cell cytoplasm. AHR is best known for mediating the toxicity of halogenated aromatics, but it has also been linked to carcinogenesis and tumor progression in several tumor types. Our aims are to assess the features of AIP immunohistochemical (IHC) staining and to evaluate its possible role as a prognostic marker in gastric cancer (GC). Retrospective study of 147 cases of resected GC. Clinicopathological features were collected, tissue microarrays were constructed for AIP IHC and statistical analysis were performed. AIP staining was observed in 50.3% of tumors. All AIP-positive cases exhibited cytoplasmic or membranous staining, variably associated with nuclear co-staining. 93.2% of AIP-positive tumors showed AIP immunoreactivity in 100% of cells. Staining intensity was mild, moderate and intense in 33.8%, 13.5% and 52.7% of cases. Tumors were stratified according to AIP staining intensity into low expression (no or mild AIP immunoreactivity) and high expression (moderate or intense AIP immunoreactivity). 36.6% of our cases showed high AIP expression. High AIP expression was significantly and independently correlated to tumor progression and cancer death. Tumors with high AIP expression showed lower survival and higher progression rates. AIP expression might be useful for determining GC prognosis. More studies are needed to clarify the role of AHR pathway in GC, AIP expression and its potential use as a surrogate marker for selecting patients for AHR modulation therapy.

Indexed as

AgedBiomarkers, TumorFemaleFollow-Up StudiesGastrectomyHumansImmunohistochemistryIntracellular Signaling Peptides and ProteinsMalePrognosisRetrospective StudiesStomach NeoplasmsSurvival Ratearyl hydrocarbon receptor-interacting proteinBiomarkers, TumorIntracellular Signaling Peptides and ProteinsAIPAryl hydrocarbon receptor interacting proteinGastric cancerImmunohistochemistryPrognosis

Identifiers

PMID32648210
OpenAlexW3042214370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.